

REIMBURSEMENT POLICY STATEMENT OHIO MARKETPLACE PLANS

Policy Name		Policy Number	Effective Date
Molecular Diagnostic Testing for		PY-0886	12/01/2019-09/30/2022
Respiratory Virus			
Po		olicy Type	
Medical	Administrative	Pharmacy	REIMBURSEMENT

Reimbursement Policy Statement: Reimbursement Policies prepared by CSMG Co. and its affiliates (including CareSource) are intended to provide a general reference regarding billing, coding and documentation guidelines. Coding methodology, regulatory requirements, industry-standard claims editing logic, benefits design and other factors are considered in developing Reimbursement Policies.


In addition to this Policy, Reimbursement of services is subject to member benefits and eligibility on the date of service, medical necessity, adherence to plan policies and procedures, claims editing logic, provider contractual agreement, and applicable referral, authorization, notification and utilization management guidelines. Medically necessary services include, but are not limited to, those health care services or supplies that are proper and necessary for the diagnosis or treatment of disease, illness, or injury and without which the patient can be expected to suffer prolonged, increased or new morbidity, impairment of function, dysfunction of a body organ or part, or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the lowest cost alternative, and are not provided mainly for the convenience of the member or provider. Medically necessary services also include those services defined in any federal or state coverage mandate, Evidence of Coverage documents, Medical Policy Statements, Provider Manuals, Member Handbooks, and/or other policies and procedures.

This Policy does not ensure an authorization or Reimbursement of services. Please refer to the plan contract (often referred to as the Evidence of Coverage) for the service(s) referenced herein. If there is a conflict between this Policy and the plan contract (i.e., Evidence of Coverage), then the plan contract (i.e., Evidence of Coverage) will be the controlling document used to make the determination.

CSMG Co. and its affiliates may use reasonable discretion in interpreting and applying this Policy to services provided in a particular case and may modify this Policy at any time.

Table of Contents

Rei	mbursement Policy Statement	1
Α.	Subject	2
	Background	
C.	Definitions.	2
	Policy	
	Conditions of Coverage	
	Related Policies/Rules.	
	Review/Revision History.	
	References	



Effective Date: 12/01/2019



Molecular Diagnostic Testing for Respiratory Virus

B. Background

Reimbursement policies are designed to assist you when submitting claims to CareSource. They are routinely updated to promote accurate coding and policy clarification. These proprietary policies are not a guarantee of payment. Reimbursement for claims may be subject to limitations and/or qualifications. Reimbursement will be established based upon a review of the actual services provided to a member and will be determined when the claim is received for processing. Health care providers and their office staff are encouraged to use self-service channels to verify member's eligibility.

It is the responsibility of the submitting provider to submit the most accurate and appropriate CPT/HCPCS code(s) for the product or service that is being provided. The inclusion of a code in this policy does not imply any right to reimbursement or guarantee claims payment.

Molecular testing, following a diagnosis or suspected diagnosis can help guide appropriate therapy by identifying specific therapeutic targets and appropriate pharmaceutical interventions. Molecular diagnostic testing utilizes Polymerase Chain Reaction (PCR), a genetic amplification technique that only requires small quantities of DNA, for example, 0.1 mg of DNA from a single cell, to achieve DNA analysis in a shorter laboratory processing time. Knowing the gene sequence, or at minimum the borders of the target segment of DNA to be amplified, is a prerequisite to a successful PCR amplification of DNA.

Molecular Diagnostic testing for the respiratory viruses known as Adenovirus, Influenza Virus, Coronavirus, Metapneumovirus, Parainfluenza Virus, Respiratory Syncytial Virus (RSV) and Rhinovirus can be utilized in the presence of symptoms such as cough, fever, headache, fatigue, rhinorrhea, pharyngitis and a general unwell feeling, that would create a clinical picture of a respiratory virus. Molecular Diagnostic testing for respiratory viruses is not indicated for every patient that presents with these signs and symptoms, as treatment is generally the same for all of the viruses and resolve with little to no pharmacological treatment, except in immunocompromised patients.

All facilities in the United States that perform laboratory testing on human specimens for health assessment or the diagnosis, prevention, or treatment of disease are regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). Waived tests include test systems cleared by the FDA for home use and those tests approved for waiver under the CLIA criteria. Although CLIA requires that waived tests must be simple and have a low risk for erroneous results, this does not mean that waived tests are completely error-proof. CareSource may periodically require review of a provider's office testing policies and procedures when performing CLIA -waived tests.

C. Definitions

- **Polymerase Chain Reaction (PCR)** a genetic amplification technique also known as a Nucleic Acid Amplification Test (NAAT).
- Medically Necessary Health care services or supplies needed to diagnosis or treat an illness, injury, condition, disease or its symptoms and that meet the accepted standards of medicine.



PY-0886

Effective Date: 12/01/2019



- I. No Prior Authorization is required for the Molecular Diagnostic Testing by PCR addressed in this policy.
- II. CareSource considers Molecular Diagnostic Testing by PCR for Respiratory Virus medically necessary when submitted with any combination of the CPT and ICD-10 diagnosis codes listed in the Conditions of Coverage in this policy.
- III. CareSource does not consider Molecular Diagnostic Testing by PCR for Respiratory Virus to be medically necessary when billed with any other ICD-10 diagnosis code and will not provide reimbursement for those services.
- IV. Conventional testing, such as rapid antigen direct tests, direct fluorescent antibody testing and cultures, are viewed as low cost and should be utilized before the higher cost Molecular Diagnostic Testing by PCR.


E. Conditions of Coverage

Reimbursement is dependent on, but not limited to, submitting Centers for Medicare & Medicaid Services (CMS) approved HCPCS and CPT codes along with appropriate modifiers. Please refer to the CMS fee schedule for appropriate codes.

The following list(s) of codes is provided as a reference. This list may not be all inclusive and is subject to updates.

CPT Code	Description		
87631	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets		
87632	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets		
87633	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets		
ICD-10 Code	Description		
B30.2	Viral pharyngoconjunctivitis		
B34.0	Adenovirus infection, unspecified		
B34.2	Coronavirus infection, unspecified		
B97.0	Adenovirus as the cause of diseases classified elsewhere		
B97.21	SARS-associated coronavirus as the cause of diseases classified elsewhere		
B97.29	Other coronavirus as the cause of diseases classified elsewhere		
B97.4	Respiratory syncytial virus as the cause of diseases classified elsewhere		





Effective Date: 12/01/2019

B97.81	Human metap neumovirus as the cause of diseases classified elsewhere		
B97.89	Other viral agents as the cause of diseases classified elsewhere		
J00	Acute nasopharyngitis [common cold]		
J05.0	Acute obstructive laryngitis [croup]		
J06.9	Acute upper respiratory infection, unspecified		
J09.X1	Influenza due to identified novel influenza A virus with pneumonia		
J09.X2	Influenza due to identified novel influenza A virus with other respiratory manifestations		
J09.X3	Influenza due to identified novel influenza A virus with gastrointestinal manifestations		
J09.X9	Influenza due to identified novel influenza A virus with other manifestations		
J10.00	Influenza due to other identified influenza virus with unspecified type of pneumonia		
J10.01	Influenza due to other identified influenza virus with the same other identified influenza virus pneumonia		
J10.08	Influenza due to other identified influenza virus with other specified pneumonia		
J10.1	Influenza due to other identified influenza virus with other respiratory manifestations		
J10.2	Influenza due to other identified influenza virus with gastrointestinal manifestations		
J10.81	Influenza due to other identified influenza virus with encephalopathy		
J10.82	Influenza due to unidentified influenza virus with myocarditis		
J10.83	Influenza due to other identified influenza virus with otitis media		
J10.89	Influenza due to other identified influenza virus with other manifestations		
J11.00	Influenza due to unidentified influenza virus with unspecified type of pneumonia		
J11.08	Influenza due to unidentified influenza virus with specified pneumonia		
J11.1	Influenza due to unidentified influenza virus with other respiratory manifestations		
J11.2	Influenza due to unidentified influenza virus with gastrointestinal manifestations		
J11.81	Influenza due to unidentified influenza virus with encephalopathy		
J11.82	Influenza due to unidentified influenza virus with myocarditis		
J11.83	Influenza due to unidentified influenza virus with otitis media		
J11.89	Influenza due to unidentified influenza virus with other manifestations		
J12.0	Adenoviral pneumonia		
J12.1	Respiratory syncytial virus pneumonia		
J12.2	Parainfluenza virus pneumonia		
J12.3	Human metap neumovirus p neumonia		
J12.81	Pneumonia due to SARS-associated coronavirus		
J12.9	Viral pneumonia, unspecified		
J20.4 J20.5	Acute bronchitis due to parainfluenza virus		
J20.5 J20.6	Acute bronchitis due to respiratory syncytial virus		
J20.9	Acute bronchitis due to rhinovirus		
J21.0	Acute Bronchidis, unspecified		
J21.9	Acute bronchiolitis due to respiratory syncytial virus Acute bronchiolitis, unspecified		
O98.511	Other viral diseases complicating pregnancy, first trimester		
J30.J11	Other viral diseases complicating pregnancy, mattimester		



Effective Date: 12/01/2019



G. Review/Revision History

	DATE	ACTION	
Date Issued	12/01/2019	New Policy	
Date Revised			
Date Effective	12/01/2019		
Date Archived	09/30/2022	This Policy is no longer active and has been archived Please note that there could be other Policies that mahave some of the same rules incorporated and CareSource reserves the right to follow CMS/State/NCCI guidelines without a formal documented Policy.	

H. References

- 1. License Agreement. (2019, January 15). Retrieved 7/29/19 from https://www.cms.gov/apps/ama/license.asp?file=/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Downloads/19CLABQ1.zip.
- 2. Medically Necessary. (2019, July 29). Retrieved 7/29/19 from https://www.healthcare.gov/glossary/medically-necessary/.
- 3. NREVSS | Home | National Respiratory and Enteric Virus Surv System | CDC. (2019, July 24). Retrieved 7/29/19 from https://www.cdc.gov/surveillance/nrevss/index.html.

The Reimbursement Policy Statement detailed above has received due consideration as defined in the Reimbursement Policy Statement Policy and is approved.

